- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02798055
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis (GRegistry SCDU)
A National, Observational, Multi-center Registry to Examine the Characteristics of Patients With Systematic Sclerosis Digital Ulcers and Assess Bosentan Treatment.
GRegistry is a significant collection of data and information on the clinical practice of systemic scleroderma finger ulcers.
The GRegistry study is a nationwide (Greece) prospective study recording, which includes consecutive patients with SC-DU diagnosis in clinical management departments of different hospitals, selected in such a way as to reflect a representation of the country.
The use of Bosentan in the treatment of patients suffering from systemic sclerosis with digital ulcer disease is supported by data from large, placebo-controlled, randomized studies. The beneficial effect of Bosentan in digital ulcers, a vascular event of systemic sclerosis consistent with its beneficial effect on pulmonary arterial hypertension associated with connective tissue disease and its beneficial effect on vascular remodeling.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The existence and use of Patient Registries, represents one of the foundations of the progressing medical science, both for studying the natural history of diseases as well as to critically evaluate the therapeutic methods, the collection and analysis of the data from a large number of hospital units, is essential. Furthermore, the assessment of the effectiveness and adequacy of health services should be based on long-term monitoring of large groups of patients, and the assessment of the efficient functioning of the individual units, is only possible only with the availability of information for the patients of these units.
Moreover, the record of health services distribution data is a prerequisite for the design of their future development. The above led to growth of many national and international patient logs, diseases and specific treatments, the operation of which has contributed to the advancement of medical science.
Scleroderma or Systemic Sclerosis (SC) is a chronic autoimmune disease of the connective tissue with an incidence of 1: 10000- 1: 30000. In Greece it is estimated that there are approximately 2,500 patients. The disease usually affects women aged 40-60 years, and the incidence is four women to one man. The pathogenesis of the disease is unknown, while the main causes are considered genetic and environmental factors.
Two of the most critical complications of the disease, are the Pulmonary Arterial Hypertension, which occurs in patients with SC approximately 8-12% of patients, being the main cause of death, and digital ulcers that occur in 30-60 % of patients and are painful sores on the fingers. Digital ulcers, i.e. painful sores on the fingers, as a consequence of the limited blood supply of vessels are seen in approximately 30-60 % of patients with scleroderma. The digital ulcers adversely affect the quality of life of patients, even the simple daily activities and can lead to serious complications, such as amputation. The symptoms of scleroderma can vary between patients and may not be typical of this disease, at least in the early stages, making it difficult to diagnose. Two of the early symptoms are disturbance of blood supply to the extremities by a color change of the skin of the fingers, alternately pallor-cyanation-redness (Raynaud phenomenon) and rigid edematous fingers.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Athens, Greece
- University Clinic, Laiko Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Both genders >18 and < 80 years
- ACR 2013 criteria >9 & =9
- At least one Digital Ulcer
- Raynaud Severity Scale (0-10)
Exclusion Criteria:
- < 18 years
- ACR 2013 criteria <9
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reynaud Severity Scale
Time Frame: 4 months
|
4 months
|
|
Number of Ulcers
Time Frame: 4 months
|
4 months
|
|
Modified Rodnan Skin Score - MRSS
Time Frame: 4 months
|
4 months
|
|
Complications of systems
Time Frame: 4 months
|
Number of organic systems which are affected by Systematic Scleroderma within last 4 months
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-BSN-EL-64
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scleroderma
-
University of Texas Southwestern Medical CenterRecruitingScleroderma, Localized | Morphea | Frontal Linear Scleroderma en Coup de Sabre | Scleroderma, Circumscribed | Scleroderma, LinearUnited States
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Gilead SciencesCompletedDiffuse Scleroderma | Limited SclerodermaAustralia
-
Mastelli S.r.lSintesi Research SrlTerminatedScleroderma DiseaseItaly
-
Lawson Health Research InstituteNovartis PharmaceuticalsTerminated
-
BiocadRecruitingSystemic SclerodermaRussian Federation
-
Rennes University HospitalCompleted
-
Castle Creek Biosciences, LLC.TerminatedScleroderma, Localized | Morphea | SclerodermaUnited States
-
Assistance Publique - Hôpitaux de ParisActelionCompleted
-
University Hospital, LilleRecruiting
Clinical Trials on Bosentan group
-
ActelionCompletedDigital UlcersFrance, United Kingdom, United States, Austria, Canada, Germany, Italy, Switzerland
-
GeropharmCompletedBioequivalenceRussian Federation
-
ActelionCompletedSystemic Sclerosis | Digital UlcersUnited States, Canada
-
ActelionCompletedPulmonary HypertensionUnited States, Canada, Australia, Germany, Italy, United Kingdom, France, Austria, Belgium, Czech Republic, Netherlands, Poland, Spain
-
Medical University of ViennaCompletedGlaucoma | Blood Flow VelocityAustria
-
ActelionCompletedPulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCanada, United Kingdom, Italy, United States, Netherlands, Australia, Austria, Belgium, France, Germany, Spain
-
ActelionCompletedInterstitial Lung Disease | SclerodermaUnited States, Korea, Republic of, Israel, France, United Kingdom, Netherlands, Switzerland, Germany, Canada, Italy, Sweden
-
General Hospital of ChalkidaUnknownSECONDARY PULMONARY HYPERTENSION | MITRAL STENOSIS | CHILDHOOD RHEUMATOID FEVER | CONGESTIVE HEART FAILUREGreece
-
Rikshospitalet University HospitalTerminated
-
University Hospital, GrenobleRecruitingIschemic Optic NeuropathyFrance